{"disease":{"id":"mixed-phenotype-acute-leukemia-in-complete-remission","name":"mixed phenotype acute leukemia in complete remission"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02578511","title":"Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Ehab L Atallah","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}